Mereo BioPharma Group plc (MREO)

Market Cap	51.08M -86.8%
Revenue (ttm)	500,000
Net Income	-41.88M
EPS	-0.26
Shares Out	159.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,018,770
Open	0.3195
Previous Close	0.3192
Day's Range	0.3100 - 0.3249
52-Week Range	0.2000 - 3.0500
Beta	0.38
Analysts	Buy
Price Target	1.50 (+368.75%)
Earnings Date	May 12, 2026

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 39
• Stock Exchange: NASDAQ
• Ticker Symbol: MREO
• Website: https://www.mereobiopharma.com

Analyst Summary

According to 5 analysts, the average rating for MREO stock is "Buy." The 12-month stock price target is $1.5, which is an increase of 368.75% from the latest price.

Price Target

$1.5

(368.75% upside)

Analyst Consensus: Buy